[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100589369":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":11,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":64,"whyStopped":11,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Qualia Life Sciences","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Qualia Senolytic","ACTIVE_COMPARATOR",null,[13],"Dietary Supplement: Qualia Senolytic",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"DIETARY_SUPPLEMENT","Qualia Senolytic manufactured by Qualia Life Science",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"William Scuba","CONTACT","855-281-2328","support@qualialife.com",[26],{"facility":5,"status":11,"city":27,"state":28,"zip":29,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Carlsbad","California","92011","United States","US",{"type":33,"coordinates":34},"Point",[35,36],-117.35059,33.15809,{"lat":36,"lon":35},[39],{"name":40,"role":22,"phone":23,"phoneExt":11,"email":24},"Abhi Argagh",{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100589369","an-open-label-pilot-study-of-qualia-senolytic-supplementation-for-the-attenuation-of-systemic-inflammatory-cytokines-100589369",false,"NCT06953518","An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text.\n* Healthy adults 45 - 79 years of age Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.\n* Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.\n* Willing to complete questionnaires, records, and diaries associated with the study.\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent",true,"ALL","45 Years","79 Years",{"count":54,"type":55},40,"ESTIMATED","INTERVENTIONAL",[58],"NA","This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.",[61],"Inflammation",[63],"Senolytic","NOT_YET_RECRUITING","2025-04-23",{"date":67,"type":68},"2025-05-01","ACTUAL",{"date":70,"type":55},"2025-05-12",{"date":72,"type":55},"2025-05-18",{"name":5,"class":6},1]